Research Shows Guillain-Barré Syndrome Remains Rare Among Older Adults After RSV Vaccination
GBS incidence slightly higher than expected in older adults after RSV vaccination, but remains rare. Arexvy (GSK) reported more serious adverse events than Abrysvo (Pfizer), though GBS rates were similar. More adverse events in 60-74 age group and women, but GBS rates consistent. Benefits of RSV vaccination outweigh risks for older adults.
Highlighted Terms
Related News
Research Shows Guillain-Barré Syndrome Remains Rare Among Older Adults After RSV Vaccination
GBS incidence slightly higher than expected in older adults after RSV vaccination, but remains rare. Arexvy (GSK) reported more serious adverse events than Abrysvo (Pfizer), though GBS rates were similar. More adverse events in 60-74 age group and women, but GBS rates consistent. Benefits of RSV vaccination outweigh risks for older adults.